These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 9809313)
21. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus. Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119 [TBL] [Abstract][Full Text] [Related]
22. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Kõks S; Soosaar A; Võikar V; Bourin M; Vasar E Neuropeptides; 1999 Feb; 33(1):63-9. PubMed ID: 10657473 [TBL] [Abstract][Full Text] [Related]
23. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system. Sherrin T; Todorovic C; Zeyda T; Tan CH; Wong PT; Zhu YZ; Spiess J Mol Psychiatry; 2009 Mar; 14(3):291-307. PubMed ID: 18195718 [TBL] [Abstract][Full Text] [Related]
24. Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis. Ballaz SJ; Bourin M Curr Neuropharmacol; 2021; 19(7):925-938. PubMed ID: 33185164 [TBL] [Abstract][Full Text] [Related]
25. Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels. Radu D; Ahlin A; Svanborg P; Lindefors N Psychopharmacology (Berl); 2002 Jun; 161(4):396-403. PubMed ID: 12073167 [TBL] [Abstract][Full Text] [Related]
28. Decreased CCK(B) receptor binding in rat amygdala in animals demonstrating greater anxiety-like behavior. Wunderlich GR; Raymond R; DeSousa NJ; Nobrega JN; Vaccarino FJ Psychopharmacology (Berl); 2002 Nov; 164(2):193-9. PubMed ID: 12404082 [TBL] [Abstract][Full Text] [Related]
29. Peripheral stimulation of CCK-B receptors by BC264 induces a hyperexploration, dependent on the delta opioid system in the nucleus accumbens of rat. Daugé V; Samir A; Cupo A; Roques BP Neuropharmacology; 1999 Jul; 38(7):999-1007. PubMed ID: 10428418 [TBL] [Abstract][Full Text] [Related]
30. Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy. Shlik J; Vasar E; Bradwejn J CNS Drugs; 1997 Aug; 8(2):134-52. PubMed ID: 23338219 [TBL] [Abstract][Full Text] [Related]
31. [Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety]. Izumi T Hokkaido Igaku Zasshi; 1998 Sep; 73(5):463-73. PubMed ID: 9846276 [TBL] [Abstract][Full Text] [Related]
32. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites. Léna I; Roques BP; Durieux C J Neurochem; 1997 Jan; 68(1):162-8. PubMed ID: 8978722 [TBL] [Abstract][Full Text] [Related]
33. Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. Ruiz-Gayo M; Durieux C; Fournié-Zaluski MC; Roques BP J Neurochem; 1992 Nov; 59(5):1805-11. PubMed ID: 1357099 [TBL] [Abstract][Full Text] [Related]
34. Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs: a microdialysis study. Rex A; Marsden CA; Fink H Neurosci Lett; 1997 Jun; 228(2):79-82. PubMed ID: 9209103 [TBL] [Abstract][Full Text] [Related]
35. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Chopin P; Briley M Psychopharmacology (Berl); 1993; 110(4):409-14. PubMed ID: 7870910 [TBL] [Abstract][Full Text] [Related]
36. Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Zwanzger P; Domschke K; Bradwejn J Depress Anxiety; 2012 Sep; 29(9):762-74. PubMed ID: 22553078 [TBL] [Abstract][Full Text] [Related]
37. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Charrier D; Dangoumau L; Puech AJ; Hamon M; Thiébot MH Psychopharmacology (Berl); 1995 Sep; 121(1):127-34. PubMed ID: 8539337 [TBL] [Abstract][Full Text] [Related]